2021
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
Verma R, Patil S, Zhang N, Moreira F, Vitorio M, Santos A, Wallace E, Gnanashanmugam D, Persing D, Savic R, Croda J, Andrews J. A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment. American Journal Of Respiratory And Critical Care Medicine 2021, 204: 1317-1326. PMID: 34375564, DOI: 10.1164/rccm.202103-0564oc.Peer-Reviewed Original ResearchConceptsPharmacogenomic assaysSparse pharmacokinetic samplingInadequate treatment responseInterindividual pharmacokinetic variabilityAcetylation genotypeIsoniazid clearancePharmacokinetic samplingPulmonary tuberculosisWhole blood samplesIntermediate acetylatorsPharmacokinetic variabilityFast acetylatorsNAT2 polymorphismsAcetylator typeSlow acetylatorsTuberculosis treatmentTreatment responseBlood samplesGeneXpert platformTuberculosis diagnosisVariable drug concentrationsHealthy individualsPersonalized dosingSubstantial incidenceStandardized dosing
2020
Genomic variant-identification methods may alter Mycobacterium tuberculosis transmission inferences
Walter KS, Colijn C, Cohen T, Mathema B, Liu Q, Bowers J, Engelthaler DM, Narechania A, Lemmer D, Croda J, Andrews JR. Genomic variant-identification methods may alter Mycobacterium tuberculosis transmission inferences. Microbial Genomics 2020, 6: mgen000418. PMID: 32735210, PMCID: PMC7641424, DOI: 10.1099/mgen.0.000418.Peer-Reviewed Original Research